FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:526-528 February 2, 2006 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Tsao, M.-S. PubMed Citation

To the Editor: Recent reports have noted the presence of novel mutations of the epidermal growth factor receptor (EGFR) gene in small samples of DNA extracted from paraffin-embedded sections or laser-microdissected specimens.^1,2 Nagahara et al.¹ reported EGFR mutations in colon carcinomas. These mutations were novel GA or AG transitions. Similarly, Tsao et al. (July 14 issue)² report that 24 (53 percent) of the mutations they found in specimens of non–small-cell lung cancers were novel variant mutations; 22 (92 percent) of these mutations were CT/GA or AG/TC transitions. These mutations had not been . . . [Full Text of this Article]

This article has been cited by other articles:

• Eberhard, D. A., Giaccone, G., Johnson, B. E. (2008). Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting. JCO 26: 983-994 [Abstract] [Full Text]  
• Bonomi, P. D., Buckingham, L., Coon, J. (2007). Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors. Clin. Cancer Res. 13: 4606s-4612s [Abstract] [Full Text]  
• Hirsch, F., Varella-Garcia, M, Cappuzzo, F, McCoy, J, Bemis, L, Xavier, A., Dziadziuszko, R, Gumerlock, P, Chansky, K, West, H, Gazdar, A., Crino, L, Gandara, D., Franklin, W., Bunn, P. Jr (2007). Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18: 752-760 [Abstract] [Full Text]  
• Daniele, L., Macri, L., Schena, M., Dongiovanni, D., Bonello, L., Armando, E., Ciuffreda, L., Bertetto, O., Bussolati, G., Sapino, A. (2007). Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Molecular Cancer Therapeutics 6: 1223-1229 [Abstract] [Full Text]  
• Sequist, L. V., Bell, D. W., Lynch, T. J., Haber, D. A. (2007). Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non-Small-Cell Lung Cancer. JCO 25: 587-595 [Abstract] [Full Text]  
• Toschi, L., Cappuzzo, F. (2007). Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. The Oncologist 12: 211-220 [Abstract] [Full Text]  
• Riely, G. J., Politi, K. A., Miller, V. A., Pao, W. (2006). Update on Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Clin. Cancer Res. 12: 7232-7241 [Abstract] [Full Text]  
• Lenz, H.-J., Van Cutsem, E., Khambata-Ford, S., Mayer, R. J., Gold, P., Stella, P., Mirtsching, B., Cohn, A. L., Pippas, A. W., Azarnia, N., Tsuchihashi, Z., Mauro, D. J., Rowinsky, E. K. (2006). Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines. JCO 24: 4914-4921 [Abstract] [Full Text]  
• Jackman, D. M., Yeap, B. Y., Sequist, L. V., Lindeman, N., Holmes, A. J., Joshi, V. A., Bell, D. W., Huberman, M. S., Halmos, B., Rabin, M. S., Haber, D. A., Lynch, T. J., Meyerson, M., Johnson, B. E., Janne, P. A. (2006). Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib.. Clin. Cancer Res. 12: 3908-3914 [Abstract] [Full Text]